Ranee Mehra

6PUBLICATIONS
52CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 15, 2026
Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study.

|Jun 10, 2025
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer.

Barbara Burtness, Yael Flamand, Harry Quon

|Jan 24, 2022
Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment.

Candice Yong, M Janelle Cambron-Mellott, Brian Seal

|Oct 26, 2021
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).

Robert L Ferris, Yael Flamand, Gregory S Weinstein

|May 07, 2020
Concurrent Definitive Immunoradiotherapy for Patients with Stage III-IV Head and Neck Cancer and Cisplatin Contraindication.

Jared Weiss, Siddharth Sheth, Allison M Deal

|Apr 21, 2020
Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date.

Michael G McCusker, Dennis Orkoulas-Razis, Ranee Mehra

Pageof 1

Frequent Collaborators

2 joint publications

Barbara Burtness

2 joint publications

Miriam N Lango

2 joint publications

R Bryan Bell

2 joint publications

Robert L Ferris